BLUE BELL, Pa., June 25 /PRNewswire/ -- TheraQuest Biosciences, a development stage pain management company today announced the appointment of Drs. Cynthia McCormick and Nathaniel Katz to its Scientific Advisory Board.
New Scientific Advisory Board Members
Cynthia McCormick, MD, is President of McCormick Consultation LLC, a consulting company providing regulatory services to the healthcare and pharmaceutical industries. Dr. McCormick was previously Director of the Food and Drug Administration’s Division of Anesthetic, Critical Care and Addiction Drug Products (since renamed the Division of Analgesics, Anti-inflammatory and Rheumatology Products). As Head of this Division, she was responsible for providing scientific and regulatory oversight for a large number of investigational and marketed analgesic products, including opioids and drugs for the treatment of neuropathic pain.
Nathaniel Katz, M.D., M.S. is President of Analgesic Research, a company providing support to pharmaceutical, healthcare and investment firms in various areas of pain management, including drug development. Dr. Katz is the former Chair of the FDA Advisory Committee for Anesthesia, Critical Care, and Addiction Products Division. He is an internationally recognized expert in pain management and analgesic clinical trials, and he has conducted numerous clinical investigations of treatments for pain, involving pharmaceuticals, non-pharmaceutical analgesics and devices, with a particular focus on opioids and risk management.
Drs. McCormick and Katz join TheraQuest’s current Scientific Advisory Board, comprising Drs. Troels Jensen, Arthur Lipman, Richard Payne, Frank Porreca and Raymond Sinatra.
Najib Babul, PharmD, President and Chief Executive Officer of TheraQuest stated, “We are very pleased that Drs. McCormick and Katz, with their significant experience in analgesic drug development and regulatory science, and their hands-on FDA experience have agreed join TheraQuest’s Scientific Advisory Board. We believe TheraQuest’s Scientific Advisory Board, consisting of world-class scientists, clinicians and regulators will help our management team optimize research and development to achieve more rapid and effective commercialization.”
About TheraQuest
TheraQuest Biosciences, Inc. ( http://www.theraquestinc.com ) is a private, development-stage pain management company building a diversified portfolio of pharmaceutical products to address a critical area of unmet medical need. Despite their limitations, current treatments for acute and chronic pain yield worldwide sales in excess of $30 billion. The TheraQuest team has contributed to the development of numerous analgesics approved in the U.S. over the past 20 years. TheraQuest’s strategy is to use its expertise to identify, develop and commercialize product candidates with strong market potential that have lower development costs and reduced regulatory risk than new chemical entities. TheraQuest is headquartered in Blue Bell, Pennsylvania.
TheraQuest is funded in part by BioAdvance, the Biotechnology Greenhouse of Southeastern Pennsylvania and Ben Franklin Technology Partners of Southeastern Pennsylvania.
TheraQuest Biosciences, Inc.
CONTACT: Najib Babul, PharmD, CEO of TheraQuest Biosciences, Inc.,inquiry@theraquestinc.com
Web site: http://www.theraquestinc.com/
